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Abnormal absorption of dietary calcium has been recognized for many years in intestinal diseases, sarcoidosis (1), idiopathic hypercalciuria (2), hypoparathyroidism (3, 4) , hyperparathyroidism (5-7), and more recently in calcinosis universalis (8) . Understanding of calcium absorption in the past has been limited by the requirement of 18 to 20 days of metabolic balance procedures; interpretation has been limited by the paucity of data in normal subjects. This paper describes a safe and simple 4 -hour isotopic test of calcium absorption that has been evaluated statistically in 21 normal subjects and in 31 patients with disorders known to alter calcium absorption.
Methods
Twenty-one normal subjects (average age, 36; range, 21 to 65 years) and 31 patients (average age, 44; range, 14 to 73 years) with disorders likely to alter calcium absorption were studied. The latter group consisted of 14 patients with disorders characterized by decreased intestinal absorption (hypoparathyroidism, celiac disease, postsurgical malabsorption, regional ileitis, and calcific pancreatitis with insufficiency) and 17 patients with disorders characterized by increased calcium absorption (hyperparathyroidism, sarcoidosis, idiopathic hypercalciuria, and calcinosis universalis). The diagnoses of intestinal malabsorption were established by the presence of steatorrhea, diminished D-xylose absorption, abnormal small bowel series, and salutary response to a gluten-free diet in the patients with celiac disease. The clinical diagnoses of hyperparathyroidism and sarcoidosis were confirmed histopathologically. One patient (A.D.) with tetany, hypocalcemia, and hyperphosphatemia was found to have idiopathic hypoparathyroidism. Patients with normal serum calcium, decreased serum phos-* Submitted for publication March 23, 1964 ; accepted September 24, 1964 . phorus, hypercalciuria that varied with calcium intake, and recurrent calcium stones were classified as having idiopathic hypercalciuria.
Twenty-four individuals were studied under metabolic balance conditions and 30 during routine ward or outpatient admissions. Calcium intake in all subjects was either known or was estimated by detailed dietary survey to range from 175 to 1,100 mg per day.
At the end of the customary 12-to 15-hour overnight fast, and 1 hour before breakfast, 5 to 10 Ac of Ca'7C12 (SA greater than 150 mc per g calcium) was administered orally in 5 ml of distilled water containing 20 mg of calcium as CaC12. During the following 4-hour period the patients were hydrated to insure a urine flow of 2 to 4 ml per minute. Venous blood was obtained for stable serum calcium measurement before the oral Ca"7 and for radioactivity measurements at 15-minute intervals for the first hour following the oral dose and at hourly intervals for the subsequent 3 hours. Urine was collected in two 2-hour periods during the 4-hour test period. Six-day stool collections following the oral dose were obtained in 27 patients. Stable calcium in plasma and urine was determined with a flame-spectrophotometric technique (9) (normal serum values range from 8.5 to 10.5 mg per 100 ml). Serum inorganic phosphorus determinations were made according to the method of Fiske and SubbaRow (10) (normal values range from 3.0 to 4.5 mg per 100 ml). Ca'7 determinations were performed on 5 ml of plasma, on 20-ml samples of each 2-hour collection, and on 200-ml samples of 6-day fecal homogenates in a well-type scintillation counter utilizing pulse-height spectrometric analysis. Discriminator settings were selected to give optimal statistical accuracy with a counting error no greater than 1%o. Energies below 400 kev were eliminated by a single-channel gammaray spectrometer to exclude the gamma emission of scandium'. In each instance samples of the administered Ca'7 test dose were also counted under identical geometric conditions, and the radioactivity of the plasma was expressed as per cent of administered dose per liter of plasma. Urine and stool radioactivity was expressed as per cent of administered dose. ;66 -H "o t-" I 00 -C4 C4 00 e 0s m t-r-o0 em " _ O C, oo o0 \0 m 0 \0 -ed 0 00 0
00 0% 00 t- .d4 4( 00 (9, 00 0 e'i 00 00 .14 (I t-- in Table I and Figure 1 . In each normal subject given Ca47, increments in blood radioactivity were observed for the first hour followed by a gradual decline during the subsequent 3-hour period. The average plasma value at 1 hour was 1 Decreased calcium absorption. The results in 14 patients with disorders in which decreased calcium absorption has been previously identified are recorded in Table III . The rate of increase in plasma radioactivity was much slower than in the normal subjects ( Figure 1 ). Peak values were delayed until 2 hours after administration of the dose, and only a slight decline in radioactivity occurred during the subsequent 2-hour period. The mean plasma Ca47 levels at each time interval were significantly lower than those in normal subjects. Despite low 1-hour plasma radioactivity values (average, 0.80; range, 0.34 to 1.10% dose per L, serum calcium concentration was normal in nine of the 14 patients studied ( Figure 2 ). Hypocalcemia was prominent in L.P., a patient with 
oo~~~~~~~~~~~~~~~~c z emb (qob4 e d0 qN 0oNmQ: (Table V) . Vitamin D increased plasma and decreased fecal Ca47 in patients J.D., L.P., M.W., and V.M. during metabolic balance studies (Table IV) (Figure 4) . By January 1964 the patient again complained of bone pain, and the serum calcium had fallen to 8.3 mg per 100 ml. Discussion The availability of radioactive isotopes of calcium and of the related alkaline earth, strontium, has stimulated search for improved methods of assessing calcium absorption. To date these have included time-consuming 12-to 14-day intrave-nous isotope infusion studies with indirect calculation of calcium absorption (12) (13) (14) , cumbersome 4-to 6-day stool radioactive measurements following oral isotope administration (15, 16) , serial analysis of plasma and urine radioactivity following oral doses of radioactive calcium or strontium (4, 5, (17) (18) (19) , and more recently, continuous external counting of bone following an oral dose of Ca47 (3). Methods heretofore advanced as "simplified" oral tests of calcium absorption commonly suffer from the lack of sufficiently large normal population studies, the administration of excessively large doses of radioactivity, and a limited number of observations in untreated patients with known disorders of calcium absorption.
The present study indicates that timed serial plasma samples following an oral dose of Ca47 reflect the intestinal ability to absorb dietary calcium. Similar observations have been made in human subjects by Bhandarkar, Bluhm, MacGregor, and Nordin (18), Samachson (4), Jaworski, Brown, Fedoruk, and Seitz (17), and Caniggia, Gennari, Bianchi, and Guideri (19) , and in rabbits by Thomas, Litovitz, and Geschickter (20) . The rapid rise in plasma radioactivity to peak levels is consistent with the results obtained by others in human beings, in whom maximal plasma radioactivity was observed normally between 1 and 2 hours following oral administration. The consistent peaking of plasma radioactivity at 1 hour observed in the present study may be attributed to the small amount of carrier stable calcium in the oral test dose, resulting in rapid absorption of Ca '7. Two factors other than absorptive mechanisms that could possibly influence plasma Ca47 levels following an oral dose include the specific activity of intestinal calcium during absorption and the size of the miscible "exchangeable" body pool of stable calcium available for the dilution of the absorbed Ca'7. Measurements of calcium concentration in gastric juice were not made during the present investigation, but its contribution was considered insignificant since reported levels of fasting gastric juice calcium are exceedingly low (2.0 to 4.5 mg per 100 ml) (21) . Moreover, these levels have been constant despite marked variations in dietary calcium (21) and in serum calcium levels (22). Since the specific activity of the test dose was identical, and since the contribution of stable calcium in the gastric juice may be assumed to be small, fluctuations in the specific activity of the absorbed Ca47 are minimized It is also unlikely that complete mixing of the oral Ca47 test dose with intestinal juice calcium takes place before absorption. Other investigators have also detected radioactive calcium in the blood 15 to 30 minutes after injection (23) indicating partial absorption in the upper intestinal tract before mixing with the digestive juices secreted into the lower intestine. The narrow range of plasma Ca47 observed in the normal subjects suggests that in fact neither gastric and intestinal juice calcium nor dietary calcium of the preceding day significantly affects the specific activity of the administered Ca47 within the 4-hour test period.
Exchangeable calcium pool estimates have been made by many investigators following intravenous doses of Ca47 or Ca45 using a variety of techniques (13, 14, (24) (25) (26) (27) . Reported values of large exchangeable calcium pools in Paget's disease (26, 27) , metastatic calcification (8), osteomalacia (28) , sarcoidosis (25) , hyperparathyroidism (26, 29) , metastatic bone disease (30, 31) , and of small pools in hypoparathyroidism (13, 26) are based on observations made during experiments varying in time from 3 hours to 10 days. Since the rate of decrease in plasma radioactivity following an oral dose of Ca47 may be presumed to be similar to that after the intravenous injection of radioactive calcium, variations in plasma Ca47 following an oral dose must also result from dilutions by the available miscible pool of body calcium. Although several authors have provided exhaustive analysis of calcium "turnover" and pool sizes utilizing polyexponential mathematical expressions, there is remarkably little information on the fate of an intravenous tracer dose of radioactive calcium within the first 1 to 2 hours following its administration and the amount of stable miscible calcium diluting the Ca47 during this period. It is apparent that the size of the rapidly miscible portion of the stable calcium pool varies directly with the amount of exchangeable bone calcium (24, 25) . However, there is evidence that the rapid decrease in plasma radioactive calcium 1 to 2 hours after its intravenous administration primarily represents mixing with extracellular fluid stable calcium (26) . Recent studies in this laboratory on the fate of an intravenous dose of (27) .
Ca47 in normal subjects in patients with known disorders of bone confirm this conclusion with close agreement for the first 90 minutes between the calculated calcium content of extracellular fluid and that obtained from the digital computer analysis of isotope disappearance curves (32) . If the plasma levels of Ca47 following an oral dose were significantly influenced by the rapidly miscible calcium pool of bone during the first 90 minutes, one would expect an indirect relationship to obtain between 1-hour plasma Ca47 levels and exchangeable calcium pool sizes. Thus, in metabolic bone disorders characterized by increased miscible pools videe supra), plasma Ca47 levels would he lower than normal, and in disorders characterized by decreased calcium pools, higher than normal. The results of the present investigation do not confirm this hypothesis (Tables II  and III) . In disorders wherein normal or increased miscible calcium pools have been documented (Table II) (Table III) consistently low following an oral dose. These latter data are consistent with the observation of malabsorption of calcium in hypoparathyroidism as cited by others (3, 4) . Thus we concluded that plasma levels of Ca47 during the first 4 hours following oral administration are determined primarily by absorption and are little affected by the exchangeable calcium pool.
A delayed absorption and subsequent plateau in oral absorption curves were characteristic of the malabsorption disorders. This "delayed absorption curve" may reflect differences in intestinal transit time in malabsorption as well as an actual decrease in calcium absorption. Since Thomas and his colleagues observed an identical pattern in rabbits when calcium chelating agents were added to the oral radioactive dose (20) , and since identical malabsorptive patterns were observed in the present investigation during sodium phytate administration ( Figure 3 and Table V) . the ob-served malabsorption pattern appears primarily to reflect a decrease in the amount of calcium absorption. Since the pattern of delayed rise in plasma Ca47 at timed intervals following the oral dose is a regular finding in patients with defective calcium absorption, the 4-hour plasma sampling test is recommended in patients suspected of calcium malabsorption. The 1-hour plasma Ca47 content ( Figure 5 ) offers a simplified and reliable alternative in situations precluding multiple venipunctures.
The specificity and sensitivity of the proposed absorption test are illustrated in the serial studies performed in J.D. (Table IV) in whom vitamin D increased Ca47 absorption, and increasing the calcium content of the diet reduced Ca47 absorption. Nicolaysen, Eeg-Larsen, and Malm (7) and Bronner, Harris, Maletskos, and Benda (15) have previously shown adaptation of the absorptive mechanism to changes in calcium content of the diet in rats and in man, and De Grazia and Rich have also published similar observations made during serial studies in normal volunteers (5) .
The calcium intake of the normal subjects varied from 486 to 1,100 mg per day. Only five of those individuals were studied during periods of supervised intake on metabolic weighed diets. The daily calcium intake of the other 16 subjects was either estimated by dietary survey or calculated and ingested without supervision. All the subjects in this group, however, represent individuals with normal gastrointestinal function and normal calcium metabolism who were studied under similar circumstances. A poor correlation between dietary calcium and 1-hour Ca47 levels was observed in these subjects (r = 0.66, Table  I ). The reproducibility of the oral Ca47 test in the same individual during a supervised calcium intake protocol was remarkably constant (J.D., B.B., L.P., Table IV The decreased absorption of Ca47 in J.D. during a period of increased calcium intake is not inconsistent with the observed lack of significant correlation between dietary calcium and 1-hour plasma Ca'7 values in the normal population, since this intestinal "adaptation" phenomenon was demonstrated in the same individual during a period of metabolic balance when the only dietary adjustment was that of increasing the calcium content. The reproducibility of the 1-hour Ca47 values in J.D., over a 6-month period, the decreased values during a period when calcium intake was increased, and the dramatic increment in plasma Ca47 activity during vitamin D ingestion (Table IV) reflect the value of serial observations in the same individual during a prolonged period of rigid dietary control.
Since there is evidence that calcium absorption is increased when dietary calcium is decreased (7, 33) , the increments in 1-hour plasma Ca47 values observed in patients with known disorders of calcium metabolism could possibly reflect intestinal absorption as conditioned by dietary alterations. Twelve of the 17 subjects with "hyperabsorptive" disorders were studied during supervised calcium intake protocols, and no correlation was noted between dietary calcium and 1-hour plasma Ca47 values (Table II) . With the exception of B.B. and M.W. (Table II) , calcium intake in this group ranged from 400 to 1,020 mg per day, with 13 patients on intakes greater than 500 mg.
Similarly, nine of the 14 patients with intestinal malabsorption were studied under metabolic balance conditions (Table III) with intakes ranging from 156 to 500 mg calcium per day. The calcium intake in this group was in general much lower than that of the normal controls (Table I) or those subjects with hyperabsorptive conditions (Table II) , and yet the 1-hour plasma Ca47 was significantly depressed. The relative increments in plasma Ca47 in hyperparathyroidism, sarcoidosis, idiopathic hypercalciuria, and calcinosis universalis despite calcium intakes approximating a gram per day, and the decreased plasma Ca47 values in malabsorptive states with relatively low calcium intakes suggest that in these patients the intestinal adaptation phenomenon demonstrated in J.D. is either lacking or overcome by their respective disease process. Since a negligible fraction of an absorbed calcium tracer is re-excreted into the intestines within 6 days (11, 34) , and since only negligible amounts of Ca45 (and Ca47) are re-excreted in the stools beyond 6 days following administration (15) (16) (17) 32) , it can be assumed that the absorbed radioactive calcium equals the administered Ca47 minus the cumulative 6-day fecal Ca47 excretion. Recent experiments wherein the adequacy of 6-day stool collections was evaluated by the simultaneous administration of nonabsorbable chromium51-labeled red blood cells and radioactive calcium suggest that this collection period is adequate for estimating the per cent of oral radioactive calcium absorbed (5) . The difference between uncorrected and true absorption (considering endogenously secreted calcium) in this series of 17 patients was always less than 7%o (5). The net absorption of radioactive calcium in normal patients approximated in this fashion agrees well with earlier observations of Brine and Johnston (34) and Bronner and associates (35) . In 27 observations herein reported there was a significant correlation (r = 0.89, p < 0.001, Figure 6 ) between the 1-hour Ca47 level and per cent absorption calculated from the 6-day stool collection. This observed correlation in normal subjects and in patients with known disorders of calcium absorption suggests that the proposed test may be used as a reliable index of calcium absorption in man. 
